Challenges and opportunities for non-antibody scaffold drugs

Rodrigo Vazquez-Lombardi¹, Tri Giang Phan¹, Carsten Zimmermann², David Lowe³, Lutz Jermutus⁴, Daniel Christ⁵

Affiliations

¹ Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia; The University of New South Wales, Faculty of Medicine, St Vincent's Clinical School, Darlinghurst, Sydney, NSW 2010, Australia.
² University of San Diego, School of Business Administration, 5998 Alcala Park, San Diego, CA 92110, USA.
³ MedImmune Ltd., Granta Park, Cambridge CB21 6GH, UK.
⁴ MedImmune Ltd., Granta Park, Cambridge CB21 6GH, UK; Trinity Hall, University of Cambridge, Trinity Lane CB2 1TJ, UK. Electronic address: jermutusl@medimmune.com.
⁵ Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia; The University of New South Wales, Faculty of Medicine, St Vincent's Clinical School, Darlinghurst, Sydney, NSW 2010, Australia. Electronic address: d.christ@garvan.org.au.

PMID: 26360055
DOI: 10.1016/j.drudis.2015.09.004

Free article

Review

Challenges and opportunities for non-antibody scaffold drugs

Rodrigo Vazquez-Lombardi et al. Drug Discov Today. 2015 Oct.

Free article

. 2015 Oct;20(10):1271-83.

doi: 10.1016/j.drudis.2015.09.004. Epub 2015 Sep 7.

Authors

Rodrigo Vazquez-Lombardi¹, Tri Giang Phan¹, Carsten Zimmermann², David Lowe³, Lutz Jermutus⁴, Daniel Christ⁵

Affiliations

¹ Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia; The University of New South Wales, Faculty of Medicine, St Vincent's Clinical School, Darlinghurst, Sydney, NSW 2010, Australia.
² University of San Diego, School of Business Administration, 5998 Alcala Park, San Diego, CA 92110, USA.
³ MedImmune Ltd., Granta Park, Cambridge CB21 6GH, UK.
⁴ MedImmune Ltd., Granta Park, Cambridge CB21 6GH, UK; Trinity Hall, University of Cambridge, Trinity Lane CB2 1TJ, UK. Electronic address: jermutusl@medimmune.com.
⁵ Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia; The University of New South Wales, Faculty of Medicine, St Vincent's Clinical School, Darlinghurst, Sydney, NSW 2010, Australia. Electronic address: d.christ@garvan.org.au.

PMID: 26360055
DOI: 10.1016/j.drudis.2015.09.004

Abstract

The first candidates from the promising class of small non-antibody protein scaffolds are now moving into clinical development and practice. Challenges remain, and scaffolds will need to be further tailored toward applications where they provide real advantages over established therapeutics to succeed in a rapidly evolving drug development landscape.

PubMed Disclaimer

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Other Literature Sources
- H1 Connect - Access expert opinions and insights on biomedical research.
- The Lens - Patent Citations Database

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Challenges and opportunities for non-antibody scaffold drugs

Affiliations

Challenges and opportunities for non-antibody scaffold drugs

Authors

Affiliations

Abstract

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources